Holen Sie sich die Stockscreener-App
6.98
7.06%
0.46
Vorhandelsmarkt:
7.01
0.03
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
GSA Capital Partners LLP Buys New Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026 - The Cryptonomist
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance? - Yahoo Finance
Iovance (IOVA) Q2 2026 Earnings Call Transcript - AOL.com
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month HighHere's What Happened - MarketBeat
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD - Investing.com
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance
IOVA Stock Quote Price and Forecast - CNN
IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast - 24/7 Wall St.
Iovance Biotherapeutics (IOVA) Is Up 48.3% After Narrowing Losses And Reaffirming 2026 Revenue Guidance - Sahm
Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns - Sahm
Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (IOVA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance? - Sahm
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? - The Motley Fool
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? - The Motley Fool
Why Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Back in Market Conversation? - Kalkine Media
Weekly Recap: IOV-LUN-202 enrollment and Q2 2026 revenue jump - TradingView
Dimensional Fund Advisors LP Purchases 1,106,592 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
What is HC Wainwright's Forecast for IOVA Q3 Earnings? - MarketBeat
Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Moomoo
Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Iovance Biotherapeutics Stock Price Forecast. Should You Buy IOVA? - StockInvest.us
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $8.00 Price Target at Citizens Jmp - MarketBeat
$Iovance Biotherapeutics (IOVA.US)$ - Moomoo
State Street Corporation (NYSE: STT) discloses 5.5% Iovance Biotherapeutics stake - Stock Titan
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect? - Yahoo Finance
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13 - Moomoo
Iovance Biotherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Form 8K Iovance Biotherapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 44.93% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Iovance Biotherapeutics Inc (IOVA) Stock News Today - TradingKey
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highl - GuruFocus
Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside - TradingView
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance
Iovance Biotherapeutics stock hits 52-week high at $5.97 By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics (NASDAQ: IOVA) files updated August 2026 presentation - Stock Titan
Iovance Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next - Yahoo Finance
IovanceStock Soars On Q2 EarningsCritical Data In Melanoma, NSCLC Due September - Seeking Alpha
Iovance Biotherapeutics (IOVA) Shares Surge 40% on Strong Q2; Ma - GuruFocus
Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30% - Investing.com
Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations - TechStock²
Iovance Biotherapeutics (IOVA) Revises 2026 Revenue Outlook Amid Strong Q2 Sales - GuruFocus
Why Iovance Biotherapeutics (IOVA) Stock Is Up Today - Quiver Quantitative
Stock Traders Buy Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week High on Strong Earnings - MarketBeat
Iovance Biotherapeutics stock hits 52-week high at $5.97 - Investing.com
Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand - Yahoo Finance
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Iovance Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IOVANCE BIOTHERAPEUTICS, INC. 2Q 2026: Revenue $99.3M, EPS $(0.11) — 10-Q Summary - TradingView
IOVA Stock Grants Signal Aggressive Post-Amtagvi Expansion - StocksToTrade
Iovance Biotherapeutics (NASDAQ: IOVA) posts Q2 2026 $99.3M revenue - Stock Titan
Earnings Flash (IOVA) Iovance Biotherapeutics Posts Q2 Loss $0.11 a Share, vs. FactSet Est of $0.13 Loss - marketscreener.com
Is Iovance Biotherapeutics (IOVA) Positioned for Growth After Q2 - GuruFocus
Earnings Flash (IOVA) Iovance Biotherapeutics, Inc. Reports Q2 Revenue $99.3M, vs. FactSet Est of $87.8M - marketscreener.com
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):